Arsham Sheybani1, Markus Lenzhofer1, Melchior Hohensinn1, Herbert Reitsamer1, Iqbal Ike K Ahmed2. 1. From the Department of Ophthalmology and Visual Sciences (Sheybani), Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, USA; Department of Ophthalmology (Lenzhofer, Hohensinn, Reitsamer), University Clinic Salzburg/SALK and Paracelsus Medical University (Reitsamer), Salzburg, Austria; Department of Ophthalmology and Vision Sciences (Ahmed), University of Toronto, Toronto, Credit Valley Eye Care (Ahmed), and Trillium Health Partners (Ahmed), Mississauga, Ontario, Canada. 2. From the Department of Ophthalmology and Visual Sciences (Sheybani), Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, USA; Department of Ophthalmology (Lenzhofer, Hohensinn, Reitsamer), University Clinic Salzburg/SALK and Paracelsus Medical University (Reitsamer), Salzburg, Austria; Department of Ophthalmology and Vision Sciences (Ahmed), University of Toronto, Toronto, Credit Valley Eye Care (Ahmed), and Trillium Health Partners (Ahmed), Mississauga, Ontario, Canada. Electronic address: ikeahmed@mac.com.
Abstract
PURPOSE: To study the effect on intraocular pressure (IOP) of implanting a new gelatin stent at the time of cataract surgery in the treatment of open-angle glaucoma (OAG). SETTING: Multicenter university and private-practice settings. DESIGN: Nonrandomized prospective clinical trial. METHODS: The implantation of 2 models of a gelatin stent (Xen140 and Xen63) was performed at the time of cataract surgery without mitomycin-C. Complete success was defined as a postoperative IOP of less than 18 mm Hg and more than a 20% reduction in IOP at 12 months without glaucoma medication. Failure was defined as loss of light perception vision or worse, a need for additional glaucoma surgery, or less than a 20% reduction in the IOP from baseline. RESULTS: The study included 37 eyes of 37 patients. The mean preoperative IOP was 22.4 mm Hg ± 4.2 (SD) on 2.5 ± 1.4 medication classes. Twelve months postoperatively, the mean IOP was reduced to 15.4 ± 3.0 mm Hg on 0.9 ± 1.0 medication classes (P < .0001). This resulted in a qualified success of 85.3% and a complete success rate off medications of 47.1%. There were no failures. CONCLUSION: Cataract surgery combined with implantation of the gelatin stent resulted in a significant reduction in IOP in eyes with OAG. FINANCIAL DISCLOSURE: Dr. Sheybani has received travel reimbursement from Aquesys, Inc. Dr. Ahmed is a paid consultant to Aquesys, Inc. No other author has a financial or proprietary interest in any material or method mentioned.
PURPOSE: To study the effect on intraocular pressure (IOP) of implanting a new gelatin stent at the time of cataract surgery in the treatment of open-angle glaucoma (OAG). SETTING: Multicenter university and private-practice settings. DESIGN: Nonrandomized prospective clinical trial. METHODS: The implantation of 2 models of a gelatin stent (Xen140 and Xen63) was performed at the time of cataract surgery without mitomycin-C. Complete success was defined as a postoperative IOP of less than 18 mm Hg and more than a 20% reduction in IOP at 12 months without glaucoma medication. Failure was defined as loss of light perception vision or worse, a need for additional glaucoma surgery, or less than a 20% reduction in the IOP from baseline. RESULTS: The study included 37 eyes of 37 patients. The mean preoperative IOP was 22.4 mm Hg ± 4.2 (SD) on 2.5 ± 1.4 medication classes. Twelve months postoperatively, the mean IOP was reduced to 15.4 ± 3.0 mm Hg on 0.9 ± 1.0 medication classes (P < .0001). This resulted in a qualified success of 85.3% and a complete success rate off medications of 47.1%. There were no failures. CONCLUSION:Cataract surgery combined with implantation of the gelatin stent resulted in a significant reduction in IOP in eyes with OAG. FINANCIAL DISCLOSURE: Dr. Sheybani has received travel reimbursement from Aquesys, Inc. Dr. Ahmed is a paid consultant to Aquesys, Inc. No other author has a financial or proprietary interest in any material or method mentioned.
Authors: Markus Lenzhofer; Clemens Strohmaier; Melchior Hohensinn; Wolfgang Hitzl; Veit Steiner; Björn Baca; Sarah Moussa; Karolina Motloch; Herbert A Reitsamer Journal: Graefes Arch Clin Exp Ophthalmol Date: 2019-09-07 Impact factor: 3.117